Already surpassing last year's total
Average technology-export deal value: $700 million
More than 10 times the 2018 level

As China rapidly emerges as a source of innovative technologies in the global drug development market, the landscape of the global pharmaceutical and biotech industries is changing quickly.

China Emerges as a Global New Drug Development Hub... Technology Exports Hit 184 Trillion Won This Year View original image

According to Reuters and other major international news outlets on October 25, the total value of technology licensing deals by Chinese pharmaceutical and biotech companies reached $139 billion (approximately KRW 184 trillion) through October 8 this year, already surpassing the full-year total of $135.7 billion (approximately KRW 179 trillion) last year. Companies that have licensed drug candidates from China include global giants such as AstraZeneca, Pfizer, Eli Lilly, AbbVie and Novartis.


Not only is the total value of licensing deals increasing, but the size of individual deals is also growing. The average value of technology export deals by Chinese pharmaceutical companies this year was approximately $700 million (approximately KRW 926 billion), about 10 times higher than in 2018.


According to an analysis by the Korea Biotechnology Industry Organization (KoreaBIO) of a report by Deloitte China, Chinese companies accounted for eight of the top 10 global pharmaceutical deals in the first half of this year. The largest was a deal signed by CSPC and AstraZeneca last January.


AstraZeneca signed a deal worth $18.5 billion (approximately KRW 25.5 trillion) to license rights to platforms related to extended-release drug delivery, which gradually releases active pharmaceutical ingredients, and artificial intelligence (AI)-based peptide discovery.


The total value of technology export deals by South Korean companies through October 15 this year is estimated at around $14.7 billion (approximately KRW 19.5 trillion).


KoreaBIO said, "China's innovation capabilities are being reassessed in the global market, supported by the increasing value of its assets, proven exit routes for investment recovery, and growing support from academia."



China's clinical trial capabilities are also improving rapidly. According to the "2025 Statistical Yearbook of the Korean Clinical Trial Industry," published recently by the Korea National Enterprise for Clinical Trials, China accounted for 15.9% of global clinical trials last year. China's share of clinical trials was 3.7% in 2017, close to South Korea's, but has risen by 12.2 percentage points in just eight years.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing